Yield10 Bioscience: Q3 Earnings Insights
Portfolio Pulse from Benzinga Insights
Yield10 Bioscience (NASDAQ:YTEN) reported Q3 earnings with an EPS of $-0.41, missing estimates by 5.13% against the expected $-0.39. Revenue declined by $111 thousand compared to the same period last year. The company's past earnings performance shows a consistent pattern of not meeting EPS estimates, with the share price remaining stable after the last earnings miss.
November 14, 2023 | 9:35 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Yield10 Bioscience reported a Q3 EPS of $-0.41, missing estimates by 5.13%, and a revenue decrease from the previous year. The company has a history of not meeting EPS estimates.
The negative earnings report, with both a miss on EPS and a decline in revenue, is likely to have a bearish impact on YTEN's stock price in the short term. Historical data shows that the company's stock price did not change significantly after the last earnings miss, but consistent underperformance may erode investor confidence over time.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100